Search research articles
Contact Us
Filters
Showing results (31-40 of 53) with videos related to
Page
of 6
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging
|
June 15, 2020
Clinical evaluation of [<sup>18</sup>F] JNJ-64326067, a novel candidate PET tracer for the detection of tau pathology in Alzheimer's disease
Mark E Schmidt, Luc Janssens, Diederik Moechars, et al.
Ebiomedicine
|
February 2, 2025
Evidence for alpha-synuclein aggregation in older individuals with hyposmia: a cross-sectional study
Kenneth Marek, David S Russell, Luis Concha-Marambio, et al.
Neurology
|
January 24, 2016
Change in PDE10 across early Huntington disease assessed by [18F]MNI-659 and PET imaging
David S Russell, Danna L Jennings, Olivier Barret, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
January 5, 2025
Quantifying VMAT2 target occupancy at effective valbenazine doses and comparing to a novel VMAT2 inhibitor: a translational PET study
Ryan Terry-Lorenzo, Daniel Albrecht, Sabrinia Crouch, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
January 22, 2025
Correction: Quantifying VMAT2 target occupancy at effective valbenazine doses and comparing to a novel VMAT2 inhibitor: a translational PET study
Ryan Terry-Lorenzo, Daniel Albrecht, Sabrinia Crouch, et al.
JAMA Neurology
|
October 17, 2014
The phosphodiesterase 10 positron emission tomography tracer, [18F]MNI-659, as a novel biomarker for early Huntington disease
David S Russell, Olivier Barret, Danna L Jennings, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
August 24, 2013
Kinetic modeling, test-retest, and dosimetry of 123I-MNI-420 in humans
Adriana Alexandre S Tavares, Jeffery C Batis, Caroline Papin, et al.
Brain Sciences
|
December 1, 2020
Reduced Expression of Cerebral Metabotropic Glutamate Receptor Subtype 5 in Men with Fragile X Syndrome
James R Brašić, Ayon Nandi, David S Russell, et al.
Brain Sciences
|
March 25, 2022
Fragile X Mental Retardation Protein and Cerebral Expression of Metabotropic Glutamate Receptor Subtype 5 in Men with Fragile X Syndrome: A Pilot Study
James Robert Brašić, Jack Alexander Goodman, Ayon Nandi, et al.
Movement Disorders Clinical Practice
|
April 11, 2017
Impact of Depression on Progression of Impairment and Disability in Early Parkinson's Disease
Danny Bega, Sheng Luo, Hubert Fernandez, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 53) with videos related to
Sort By:
Page
of 6
European Journal of Nuclear Medicine and Molecular Imaging
|
June 15, 2020
Clinical evaluation of [<sup>18</sup>F] JNJ-64326067, a novel candidate PET tracer for the detection of tau pathology in Alzheimer's disease
Mark E Schmidt, Luc Janssens, Diederik Moechars, et al.
Ebiomedicine
|
February 2, 2025
Evidence for alpha-synuclein aggregation in older individuals with hyposmia: a cross-sectional study
Kenneth Marek, David S Russell, Luis Concha-Marambio, et al.
Neurology
|
January 24, 2016
Change in PDE10 across early Huntington disease assessed by [18F]MNI-659 and PET imaging
David S Russell, Danna L Jennings, Olivier Barret, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
January 5, 2025
Quantifying VMAT2 target occupancy at effective valbenazine doses and comparing to a novel VMAT2 inhibitor: a translational PET study
Ryan Terry-Lorenzo, Daniel Albrecht, Sabrinia Crouch, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
January 22, 2025
Correction: Quantifying VMAT2 target occupancy at effective valbenazine doses and comparing to a novel VMAT2 inhibitor: a translational PET study
Ryan Terry-Lorenzo, Daniel Albrecht, Sabrinia Crouch, et al.
JAMA Neurology
|
October 17, 2014
The phosphodiesterase 10 positron emission tomography tracer, [18F]MNI-659, as a novel biomarker for early Huntington disease
David S Russell, Olivier Barret, Danna L Jennings, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
August 24, 2013
Kinetic modeling, test-retest, and dosimetry of 123I-MNI-420 in humans
Adriana Alexandre S Tavares, Jeffery C Batis, Caroline Papin, et al.
Brain Sciences
|
December 1, 2020
Reduced Expression of Cerebral Metabotropic Glutamate Receptor Subtype 5 in Men with Fragile X Syndrome
James R Brašić, Ayon Nandi, David S Russell, et al.
Brain Sciences
|
March 25, 2022
Fragile X Mental Retardation Protein and Cerebral Expression of Metabotropic Glutamate Receptor Subtype 5 in Men with Fragile X Syndrome: A Pilot Study
James Robert Brašić, Jack Alexander Goodman, Ayon Nandi, et al.
Movement Disorders Clinical Practice
|
April 11, 2017
Impact of Depression on Progression of Impairment and Disability in Early Parkinson's Disease
Danny Bega, Sheng Luo, Hubert Fernandez, et al.
Page
of 6